# Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

> **NCT03531281** · PHASE1 · WITHDRAWN · sponsor: **City of Hope Medical Center**

## Conditions studied

- Hematopoietic and Lymphoid Cell Neoplasm
- Hematopoietic Cell Transplantation Recipient

## Interventions

- **PROCEDURE:** Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **DRUG:** Goat Milk
- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Palifermin
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus
- **RADIATION:** Total-Body Irradiation

## Key facts

- **NCT ID:** NCT03531281
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-12-30
- **Primary completion:** 2022-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Administratively withdrawn
- **Last updated:** 2018-12-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03531281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03531281, "Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03531281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*